Check-Cap Company Profile (NASDAQ:CHEK)

Check-Cap trades on the NASDAQ under the ticker symbol "CHEK."

Check-Cap Ltd. (NASDAQ:CHEK) issued its quarterly earnings results on Thursday, August, 10th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.16) by $0.01. View Check-Cap's Earnings History.

Check-Cap is scheduled to release their next quarterly earnings announcement on Wednesday, November, 15th 2017. View Earnings Estimates for Check-Cap.

3 equities research analysts have issued 1 year target prices for Check-Cap's stock. Their forecasts range from $5.00 to $7.00. On average, they anticipate Check-Cap's stock price to reach $6.00 in the next year. View Analyst Ratings for Check-Cap.

Here are some recent quotes from research analysts about Check-Cap stock:

• 1. According to Zacks Investment Research, "Check Cap Ltd. is a medical diagnostics company. The company is engaged in the development of an ingestible imaging capsule for the screening of colorectal cancer. Check Cap Ltd. is based in Mount Carmel, Israel. " (10/3/2017)
• 2. Maxim Group analysts commented, "Summary Check-Cap announced that the company has filed for the CE Mark registration of C-Scan. Sure, that is positive news. We worry that the reported 44% sensitivity" in N=45 subjects is low but we see room for that number to rise with improved software. The press release goes on to state that in the analysis for polyps, specificity was 89%". Sensitivity strongly correlated (R-squared = 0.98) to the percentage of the colon scanned. Sensitivity was 78% (p<0.05) and 100% (p<0.05) for subjects where greater than 50% and 70% of the colon was scanned, respectively. Specificity was consistent for all subjects. We conclude that for CE Mark and in Europe where the standard of care is comparable (stool test) that the data should support an approval. We also recognize however that the US standard will be much higher as the US comparison must be colonoscopy (85-90%) sensitive."" (9/27/2017)
• 3. HC Wainwright analysts commented, "We note that this trial is designed to evaluate C-Scan’s ability to detect polyps as compared to colonoscopy. We expect a total data package of around 150 subjects to be submitted for CE Mark approval, which may potentially lead to European market entry in 2018. In the wake of this update, we reiterate our Buy rating and $6 price target. GE Healthcare collaboration awarded $1M grant. Check-Cap and GE Healthcare (GE; not rated) received approval of a $1M conditional grant from the Israel-U.S. Binational Industrial Research and Development Foundation (BIRD). The grant is to support development of a high- volume manufacturing process for the C-Scan system’s X-ray source and capsule assembly, and establish a unique product distribution process for a pilot clinical trial in the U.S." (8/11/2017)
• 4. Rodman & Renshaw analysts commented, "We are initiating coverage of Check-Cap Ltd., a clinical-stage medical diagnostic company developing a next-generation colorectal cancer (C RC) detection system, with a Buy rating and a 12-month price target of $6.00 per share. In our view, the company's ingestible X-ray scanning capsule, the C-Scan?? screening system, is differentiated from other structural visualization methods- e.g., optical colonoscopy, computed tomographic colonography (CTC) and other optical capsules - since it eliminates the troublesome preparatory step of bowel cleansing, which is the primary reason that many people over age 50 choose not to undergo colonoscopy-based CRC screening. In removing the need for laxative prep and allowing people to maintain normal activities during the imaging process, Check-Cap's system could persuade more people to have regular CRC screening as well as seize market share from the existing screening population. Check-Cap's system candeliver structural imaging of the colon without the pain, discomfort and embarrassment due to the invasive process of colonoscopy." (1/19/2017)

Some companies that are related to Check-Cap include Xenon Pharmaceuticals (XENE), Viking Therapeutics (VKTX), KemPharm (KMPH), ContraVir Pharmaceuticals (CTRV), Prima BioMed Ltd (PBMD), Evoke Pharma (EVOK), Proteostasis Therapeutics (PTI), SCYNEXIS (SCYX), Cancer Genetics (CGIX), Microbot Medical (MBOT), Bellerophon Therapeutics (BLPH), Biolase (BIOL), Aptevo Therapeutics (APVO), Juniper Pharmaceuticals (JNP), Catabasis Pharmaceuticals (CATB), Concordia International Corp. (CXRX), TRACON Pharmaceuticals (TCON) and OvaScience (OVAS).

Check-Cap's management team includes the folowing people:

• Tomer Kariv J.D., Chairman of the Board
• William Densel, Chief Executive Officer, Director
• Lior Torem CPA, Chief Financial Officer
• Yoav Kimchy Ph.D., Chief Technology Officer
• Alex Ovadia, Vice President - Research & Development
• Mary Jo Gorman M.D., External Director
• XiangQian Lin, Director
• Walter L. Robb Ph.D., Director
• Yuval Yanai, External Director
• Steven J. Hanley, Independent Director

(CHEK) raised $13 million in an initial public offering on Thursday, February 19th 2015. The company issued 1,200,000 shares at a price of $10.00-$12.00 per share. Chardan Capital Markets and Maxim Group acted as the underwriters for the IPO and Feltl and Company was co-manager.

Shares of Check-Cap can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Check-Cap stock can currently be purchased for approximately $1.71.